Search

Zentalis Pharmaceuticals Inc

Uždarymo kaina

3.53 -14.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.5

Max

4.13

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-42M

-78M

Pelnas, tenkantis vienai akcijai

-0.59

Darbuotojai

106

EBITDA

-42M

-77M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+112.77% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-34M

297M

Ankstesnė atidarymo kaina

18.06

Ankstesnė uždarymo kaina

3.53

Zentalis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 23:56; UTC

Columbia Banking System Inc shares are higher in after-market trading, maintaining an upward trend since Friday's close, with no specific news identified for the movement.

2026-08-14 23:56; UTC

Lowe's Companies Inc saw modest gains during after-market hours, trading near the upper end of its one-month range and above its 20-day moving average.

2026-08-14 23:56; UTC

CEVA Inc shares are higher in after-market trading, reaching a session high earlier. The stock remains within its one-month trading range.

2026-08-14 23:56; UTC

Whirlpool Corp shares are trading lower in after-market hours. No specific news was identified to explain the movement.

2026-08-14 23:56; UTC

ETF Constituents

Vanguard FTSE Developed Markets ETF rises in after-market trading, supported by strong performances from top holdings including UL, KB, SAP, FLUT, and CVE.

2026-08-14 23:56; UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

2026-08-14 23:56; UTC

Aptiv PLC shares are trading higher in after-market hours following an early spike, amid a market characterized by complacency and stable equities.

2026-08-14 23:56; UTC

Fox Corp shares are lower in after-market hours, showing unusual volatility. No specific news was identified to explain the movement.

2026-08-14 23:56; UTC

Encore Capital Group Inc shares are higher in after-market trading, continuing a positive trend following four consecutive sessions of gains. No specific news was identified.

2026-08-14 23:56; UTC

Commercial Metals Co. shares declined after-market, continuing a trend of three consecutive lower daily closes, despite remaining above the 20-day moving average.

2026-08-14 23:56; UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund is trading higher in after-market hours, supported by gains from top holdings like Monster Beverage and Walmart.

2026-08-14 23:56; UTC

Macro News
ETF Constituents

VanEck Gold Miners ETF rises in after-market trading amid U.S.-Iran tensions and a weaker U.S. Dollar Index, boosting demand for safe-haven assets.

2026-08-14 23:56; UTC

Cognizant Technology Solutions shares are higher in after-market trading, recovering from earlier losses amid a mixed backdrop in global equity markets.

2026-08-14 23:52; UTC

News

Boeing Co secures over $711 million in U.S. defense contract modifications, boosting investor sentiment. Shares are higher in after-market trading.

2026-08-14 23:51; UTC

Insight Enterprises Inc. shares are trading slightly lower after-market, amid broader market concerns following a surprising decline in U.S. retail sales for July.

2026-08-14 23:51; UTC

Turning Point Brands Inc shares are higher in after-market hours, trading above their 20-day moving average amid broader market concerns over declining U.S. retail sales.

2026-08-14 23:51; UTC

ETF Constituents

Energy Select Sector SPDR Fund rose in after-market hours, driven by gains from Valero Energy, Chevron, and Exxon Mobil, offsetting minor declines from Marathon and Occidental.

2026-08-14 23:51; UTC

Vipshop Holdings Ltd shares are higher in after-market hours, diverging from recent declines despite a drop in U.S. retail sales for July.

2026-08-14 23:51; UTC

Kanzhun Ltd. shares are lower in after-market hours, reflecting a decline following disappointing U.S. retail sales data and shifting market sentiment on interest rates.

2026-08-14 23:51; UTC

Cognex Corp shares are lower in after-market hours amid broader market concerns following a decline in U.S. retail sales for July.

2026-08-14 23:51; UTC

Abercrombie & Fitch Co shares are lower in after-market hours following a decline in U.S. retail sales for July, raising concerns about consumer spending.

2026-08-14 23:51; UTC

RingCentral Inc. shares are higher in after-market trading, reflecting positive momentum following Friday's close, despite concerns over July's U.S. retail sales decline.

2026-08-14 23:51; UTC

Social Media

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

2026-08-14 23:51; UTC

Tower Semiconductor shares are higher in after-market trading, remaining above their 20-day moving average despite a decline in U.S. retail sales for July.

2026-08-14 23:51; UTC

Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.

2026-08-14 23:51; UTC

News

PayPal is in advanced talks for a potential sale to Stripe and Advent, following a proposal of $60.50 per share. Shares are higher in after-market trading.

2026-08-14 23:51; UTC

China's House Price Index YoY release on August 17, 2026, signals cautious market sentiment amid ongoing housing challenges and weak demand.

2026-08-14 23:51; UTC

Social Media

BJ's Wholesale Club Holdings Inc. is trading higher in after-market hours following its scheduled earnings report amid positive market sentiment despite a drop in U.S. retail sales.

2026-08-14 23:51; UTC

Griffon Corp shares are lower in after-market hours amid weak market sentiment and disappointing U.S. retail sales data, which diverged from expectations.

2026-08-14 23:51; UTC

In after-market trading, Bloomin' Brands Inc is moving higher, reflecting strong performance despite a decline in U.S. retail sales for July.

Akcijų palyginimas

Kainos pokytis

Zentalis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

112.77% į viršų

12 mėnesių prognozė

Vidutinis 8.83 USD  112.77%

Aukščiausias 11 USD

Žemiausias 5 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zentalis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

5

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat